US Bancorp’s Compass Therapeutics CMPX Stock Holding History

US Bancorp’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-77	Closed	-$407	–	4192
2026 Q1	$407	Buy	+77	New	+$444	﹤0.01%	4021
2025 Q2	–	Sell	-65	Closed	-$124	–	4186
2025 Q1	$124	Buy	+65	New	+$173	﹤0.01%	4132

Other funds holding CMPX

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

US Bancorp's CMPX Position: Q2 2026 in Review

US Bancorp sold out of Compass Therapeutics (CMPX) in Q2 2026, closing a stake of 77 shares — an estimated $407 sold.

US Bancorp first reported a position in CMPX in Q1 2025 and held it in 2 quarters. The position peaked at $407 in Q1 2026. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

US Bancorp reported no remaining Compass Therapeutics position as of Q2 2026 after selling out during the quarter.
US Bancorp sold 77 Compass Therapeutics shares in Q2 2026, an estimated $407.
US Bancorp first reported a position in Compass Therapeutics in Q1 2025 and held it in 2 quarters.
US Bancorp's Compass Therapeutics position peaked at $407 in Q1 2026.
215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.